Medincell’s Post

What Are the Latest Innovations in #DryEyeSyndromeTreatments? The rising prevalence of eye conditions, including dry eyes, eye #inflammation, and cataracts, has led to an increased demand for treatments within the #dryeye syndrome industry. This growing patient population seeking relief from these conditions has stimulated the development and expansion of #treatmentsandtherapies, thus driving the growth of the dry eye syndrome #treatmentssector. Key Market Players: AbbVie., Johnson & Johnson, AFT Pharmaceuticals , Novartis, Bausch Health Companies Inc., Viatris., Santen Pharmaceutical , Novaliq GmbH, Alcon, SUN PHARMACEUTICAL JSC Want to Know More: https://lnkd.in/dAdSet4i #AMR #EyeHealth #DryEyeSyndrome #CataractAwareness #EyeCare #InflammationRelief #VisionHealth #EyeWellness #Ophthalmology #EyeTreatment 

🔔 Exciting Update from Our Partnership with Teva Pharmaceuticals!   Today, Teva has shared some compelling updates regarding our partnered programs:   🌟 Revenue projections: For the year 2024, UZEDY™ is expected to achieve an estimated revenue of around $80 million.   🌟 Clinical advancements: In the Phase 3 clinical trials for Olanzapine LAI, no Post-Injection Delirium/Sedation Syndrome (PDDS) observed to date.   Both UZEDY™ and Olanzapine LAI are shining examples of the innovative Long-Acting Injectable (LAI) technology pioneered by MedinCell.   Read the press release: https://lnkd.in/ePCtChae   Stay tuned for more updates!   #Schizophrenia #HealthcareInnovation #PartnershipSuccess #MedinCell #TevaPharmaceuticals #UZEDY #ClinicalTrials

#Alopecia_Treatment Market Share Charges Ahead with Huge Growth 2022-2030 https://lnkd.in/dPmP_DkK The rising cases of #hair loss because of #chronic disorders and stress coupled with the advancement in the hair #loss treatment are the prominent factors propelling the #market growth. Rising #disposable income and growing sense of #aesthetic appeal are further expected to fuel the #market demand. SUN PHARMACEUTICAL JSC Aclaris Therapeutics, Inc. Cipla Concert Pharmaceuticals, Inc. Daiichi Sankyo, Inc. Daiichi Sankyo Brasil Ltda #treatment

BioNJ's inaugural AI & Digital Health Day is coming up on November 1st and will feature experts from across the life science industry like Anna Sandler at Teva Pharmaceuticals. Anna will discuss some of the opportunities and pitfalls of bringing a successful digital health solution to market. If you are an entrepreneur working in AI or digital health, you won't want to miss this event! Morgan Stanley DLA Piper #BioNJEntrepreneurs #DigitalHealth #NJInnovation

🗣  A huge shoutout to the team at Lexicon Pharmaceuticals, Inc. as they seek to improve the quality of life for patients fighting through a common side effect of diabetes - pain from nerve damage. ❓ Did you know that as many as 50% of patients with diabetes suffer nerve damage related to the disease? This condition - known as diabetic neuropathy - can mean 2 extreme realities: 😖  Increased pain in their feet, legs and hands that make navigating life more difficult. ❗  Less feeling makes it more likely that minor injuries in those extremities turn into severe infections with dire long-term results - including amputation. 🤞🏿  Lexicon’s PROGRESS study (currently in Phase 2b) is the next step as the team seeks approval for a new, non-opioid drug to treat this pain. Its approval would be the first of its kind in more than 2 decades! 👏🏿  This is the type of project that fulfills the Medidata mission to “power smarter treatments and healthier people.” We’re thankful to partner with the team at Lexicon to PROGRESS this effort (pun absolutely intended)! #customerappreciation #DCT #EDC #decentralizedclinicaltrials #medidata #diabetes #patientadvocacy #patientcloud #clinicaltrials #diabeticperipheralneuropathy #electronicdatacapture #patientcloud Medidata Solutions Dassault Systèmes Phyllisa Deroze, PhD Alicia C. Staley Karen J. Wood Anthony Costello Meg Domanico Hood Steve Silverberg Matt Noble Lonnel Coats

Apellis Pharmaceuticals Inc (NASDAQ:APLS) #investors enjoyed some financial schadenfreude, with its stock rising over 9% in early deals after rival Astellas Pharma Inc. failed in a trial of an intended treatment for age-related macular degeneration. The failure faced by Japanese #biopharma leaves the market opportunity open for #Apellis, which has been having its own clinical challenges. Last month, #ApellisPharmaceuticals got a share price boost after it updated investors regarding an ongoing safety review of injection kits used with SYFOVRE, the company's treatment for eye disease. A review was previously launched after reports of rare side effects—a form of eye inflammation known as retinal vasculitis. It added that issues had been identified regarding the use of 19-gauge filter needles in certain injection kits and that the company recommends the use of 18-gauge filter needles. More at #Proactive #ProactiveInvestors http://ow.ly/exz4104UJtA

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) CEO Brian Strem joined Steve Darling from Proactive to share news the company's plan to broaden the clinical development of KIO-301, a treatment designed for various inherited retinal diseases. The expansion includes initiating a Phase 2 trial which will be controlled, double-masked, randomized, and will involve an ascending-dose. This trial is set to include up to 20 patients suffering from Retinitis Pigmentosa (RP), who will receive doses monthly over a span of 90 days. Strem explained that this move is propelled by encouraging topline results from a Phase I/II clinical trial, which indicated that KIO-301 is a first-in-class small molecule with significant potential to improve vision for patients with RP, even those with extremely low vision or complete blindness. Moreover, Kiora Pharmaceuticals has plans to engage with the FDA in the fourth quarter of 2023. Watch at #Proactive #ProactiveInvestors #NASDAQ #KPRX http://ow.ly/2e8m1052gy1

What Factors Are Driving the Growth of the #NeuropathicPain Market? The growth of the neuropathic pain market is driven by the rising demand for pain management drugs, government initiatives to increase awareness, and a surge in clinical trials. For example, Algiax Pharmaceuticals' Phase 2a study update on AP-325 (NCT04429919) confirmed safety and progression, highlighting ongoing advancements in chronic neuropathic pain treatment. Want To Know More: https://lnkd.in/dMWbZ34P #NeuropathicPain #DrugDevelopment #ClinicalTrials #PainManagement #HealthcareInnovation